AntriaBio Inc  

(Public, OTCMKTS:ANTB)   Watch this stock  
Find more results for antb
+0.010 (1.96%)
Apr 22 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.52 - 0.52
52 week 0.20 - 1.19
Open 0.52
Vol / Avg. 237.00/4,546.00
Mkt cap 20.80M
P/E     -
Div/yield     -
EPS -0.21
Shares 40.00M
Beta     -
Inst. own     -

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -484.78% -619.32%
Return on average equity - -
Employees 3 -
CDP Score - -


890 Santa Cruz Avenue
United States - Map
+1-650-2419330 (Phone)
+1-302-6365454 (Fax)

Website links


AntriaBio, Inc., formerly Fits My Style Inc. is a biopharmaceutical company developing novel therapeutic products for the diabetes market. The Company´┐Żs product pipeline includes AB101 and AB201 (Long acting GLP-1). AB101 is PEGylated basal insulin that has been formulated in biodegradable microspheres to be injected weekly to treat patients with Type 1 and Type 2 diabetes who require basal insulin to control hyperglycemia. Glucagon-like peptide-1 (GLP) is a naturally occurring peptide in the intestine that helps control glucose levels by stimulating the pancreas to produce insulin, reducing the amount of glucose that is produced by the liver, reducing the rate at which the stomach digests food and empties into the small intestine (gastric emptying) and curbing the appetite and the amount of food that is consumed. As of February 6, 2013, the Company had not generated any revenue.

Officers and directors

Nevan C. Elam Chairman of the Board, President, Chief Executive Officer
Age: 45
Sankaram Mantripragada Ph.D. Chief Scientific Officer
Age: 54
Steve R. Howe Director
Age: 60
Hoyoung Huh M.D., Ph.D. Director
Age: 43
Nickolay V. Kukekov Ph.D. Director
Age: 39